Enhancement of Therapeutic Potential of Oncolytic Virus with Homologous Tumor Cell Membranes for Pancreatic Cancer

Overview

Journal IET Nanobiotechnol

Publisher Wiley

Specialty Biotechnology

Date 2024 Jun 12

PMID 38863971

Authors

Wei Chen

Hui Liu

Yue Chen

Meng Gao

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is a leading cause of cancer-related deaths worldwide. Conventional therapies often provide limited success, necessitating the need for novel therapeutic strategies. Oncolytic viruses (OVs) are a class of viruses that specifically target and kill cancer cells while leaving normal cells unharmed. These viruses have shown promise in the treatment of various cancers, including pancreatic cancer. However, their use in clinical settings has been limited by several factors. Their inability to efficiently infect and kill tumor cells. To overcome this limitation, a cell membrane-coated oncolytic virus was developed. However, the necessity of homologous and nonhomologous tumor cell membranes for their function has not yet been proven. This novel virus displayed increased infectivity and killing activity against tumor cells compared to nonhomologous tumor cell membranes and noncoated viruses. We believe that the homologous tumor cell membranes-coated OVs can enhance the therapeutic potential for pancreatic cancer therapy.

References

Ferguson M, Lemoine N, Wang Y . Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012; 2012:805629. PMC: 3287020. DOI: 10.1155/2012/805629. View

Chiocca E . Oncolytic viruses. Nat Rev Cancer. 2002; 2(12):938-50. DOI: 10.1038/nrc948. View

Vaha-Koskela M, Heikkila J, Hinkkanen A . Oncolytic viruses in cancer therapy. Cancer Lett. 2007; 254(2):178-216. PMC: 7126325. DOI: 10.1016/j.canlet.2007.02.002. View

Nakashima H, Kaur B, Chiocca E . Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev. 2010; 21(2-3):119-26. PMC: 3109423. DOI: 10.1016/j.cytogfr.2010.02.004. View

Power A, Bell J . Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther. 2007; 15(4):660-5. DOI: 10.1038/sj.mt.6300098. View

Minna J, Roth J, Gazdar A . Focus on lung cancer. Cancer Cell. 2002; 1(1):49-52. DOI: 10.1016/s1535-6108(02)00027-2. View

Travis W . Pathology of lung cancer. Clin Chest Med. 2002; 23(1):65-81, viii. DOI: 10.1016/s0272-5231(03)00061-3. View

Thakur A, Parra D, Motallebnejad P, Brocchi M, Chen H . Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact Mater. 2021; 10:281-294. PMC: 8636666. DOI: 10.1016/j.bioactmat.2021.08.029. View

Hemminki O, Dos Santos J, Hemminki A . Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020; 13(1):84. PMC: 7325106. DOI: 10.1186/s13045-020-00922-1. View

10.

de Groot P, Wu C, Carter B, Munden R . The epidemiology of lung cancer. Transl Lung Cancer Res. 2018; 7(3):220-233. PMC: 6037963. DOI: 10.21037/tlcr.2018.05.06. View

11.

Schabath M, Cote M . Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1563-1579. PMC: 6777859. DOI: 10.1158/1055-9965.EPI-19-0221. View

12.

Wedge M, Jennings V, Crupi M, Poutou J, Jamieson T, Pelin A . Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. Nat Commun. 2022; 13(1):1898. PMC: 8990073. DOI: 10.1038/s41467-022-29526-8. View

13.

Yaghchi C, Zhang Z, Alusi G, Lemoine N, Wang Y . Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy. 2015; 7(12):1249-58. PMC: 4976866. DOI: 10.2217/imt.15.90. View

14.

Hill C, Carlisle R . Achieving systemic delivery of oncolytic viruses. Expert Opin Drug Deliv. 2019; 16(6):607-620. DOI: 10.1080/17425247.2019.1617269. View

15.

Stevenson A, Giles M, Hall K, Goodwin D, Calderwood M, Markham A . Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells. Br J Cancer. 2000; 83(3):329-32. PMC: 2374565. DOI: 10.1054/bjoc.2000.1346. View

16.

Ady J, Heffner J, Klein E, Fong Y . Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virother. 2016; 3:35-46. PMC: 4918362. DOI: 10.2147/OV.S53858. View

17.

Atasheva S, Shayakhmetov D . Oncolytic Viruses for Systemic Administration: Engineering a Whole Different Animal. Mol Ther. 2021; 29(3):904-907. PMC: 7934625. DOI: 10.1016/j.ymthe.2021.02.001. View

18.

Oroojalian F, Beygi M, Baradaran B, Mokhtarzadeh A, Shahbazi M . Immune Cell Membrane-Coated Biomimetic Nanoparticles for Targeted Cancer Therapy. Small. 2021; 17(12):e2006484. DOI: 10.1002/smll.202006484. View

19.

Cook M, Chauhan A . Clinical Application of Oncolytic Viruses: A Systematic Review. Int J Mol Sci. 2020; 21(20). PMC: 7589713. DOI: 10.3390/ijms21207505. View

20.

Santos J, Heinio C, Quixabeira D, Zafar S, Clubb J, Pakola S . Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. Cells. 2021; 10(5). PMC: 8143525. DOI: 10.3390/cells10050978. View